Golden State Equity Partners’s Carisma Therapeutics CARM Stock Holding History

Golden State Equity Partners’s Portfolio CARM Stock Details CARM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-200	Closed	-$6	–	546
2026 Q1	$6	Buy	+200	New	+$6	﹤0.01%	2018

Other funds holding CARM

UBP

Union Bancaire Privee Geneva 1, Switzerland $9.16B AUM 31.4% 1-Year Est. Return

Golden State Equity Partners's CARM Position: Q2 2026 in Review

Golden State Equity Partners sold out of Carisma Therapeutics (CARM) in Q2 2026, closing a stake of 200 shares — an estimated $6 sold.

Golden State Equity Partners first reported a position in CARM in Q1 2026 and held it in 1 quarter. The position peaked at $6 in Q1 2026. 1 fund tracked by Wall St. Rank holds CARM as of Q2 2026.

Golden State Equity Partners reported no remaining Carisma Therapeutics position as of Q2 2026 after selling out during the quarter.
Golden State Equity Partners sold 200 Carisma Therapeutics shares in Q2 2026, an estimated $6.
Golden State Equity Partners first reported a position in Carisma Therapeutics in Q1 2026 and held it in 1 quarter.
Golden State Equity Partners's Carisma Therapeutics position peaked at $6 in Q1 2026.
1 fund tracked by Wall St. Rank held Carisma Therapeutics as of Q2 2026.

Based on Golden State Equity Partners's 13F filing for Q2 2026, filed 30 Jul 2026.